Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB sets down plans for CEO succession

UCB sets down plans for CEO succession

20th February 2014

UCB has announced that Jean-Christophe Tellier is to become its next chief executive officer (CEO) as of January 1st 2015.

Mr Tellier, currently the company's executive vice-president of biopharma brands and solutions, will be appointed CEO-elect and chairman of the executive committee on March 1st, and will also be proposed as a member of the board of directors at UCB's annual general meeting on April 24th.

The firm has planned an orderly handover period that will take place throughout the remainder of 2014, during which Mr Tellier will work alongside current CEO Roch Doliveux to ensure a seamless transition.

In the last decade, UCB has evolved from a diversified chemical company into a global biopharmaceutical leader, allowing it to overcome the challenge of the patent cliff. It is now entering into a new phase of growth, with its late-stage pipeline set to reach pivotal milestones from the second half of 2014 through to mid- 2016. 

Gerhard Mayr, chairman of the board of directors, said: "Roch has put everything in place to prepare UCB for its next phase. We wish to express our gratitude for everything he has done for UCB and the patients who rely on our innovative products worldwide."

The company has become a global biopharmaceutical company with a focus on severe diseases. It now has operations in approximately 40 countries worldwide.ADNFCR-8000103-ID-801695611-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.